Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse

Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse

Although first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy is effective for treating EGFR-mutant non–small cell lung cancer (NSCLC), it is now understood that drug-tolerant persister (DTP) cells escaping from initial treatment eventually drives drug resistanc...

Full description

Bibliographic Details
Main Authors: Meng Nie, Na Chen, Huanhuan Pang, Tao Jiang, Wei Jiang, Panwen Tian, LiAng Yao, Yangzi Chen, Ralph J. DeBerardinis, Weimin Li, Qitao Yu, Caicun Zhou, Zeping Hu
Format: Article
Language:English
Published: American Society for Clinical Investigation 2022-10-01
Series:The Journal of Clinical Investigation
Subjects:
Metabolism
Oncology
Online Access:https://doi.org/10.1172/JCI160152

Internet

https://doi.org/10.1172/JCI160152

Similar Items